@article{ATM21037,
author = {Uru Nezu Osada and Yasuo Terauchi},
title = {The new basal insulin analog glargine U-300 enables flexible injection schedule},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Recently, Home et al. published a pre-planned continuation trial of EDITION 4 (1). EDITION 4 was a 6-month long, multicenter, randomized, and open-label clinical trial involving patients with type 1 diabetes mellitus (T1DM) who received a morning or evening injection of either 300 U/mL of insulin glargine (Gla-300) or 100 U/mL of insulin glargine (Gla-100) (1) to evaluate the safety, tolerability, and efficacy of both the dosages of the basal insulin analog.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21037}
}